Frost, Adaani E. ; Barst, Robyn J. ; Hoeper, Marius M. 
; Chang, Hyuk-Jae ; Frantz, Robert P. ; Fukumoto, Yoshihiro ; Galié, Nazzareno ; Hassoun, Paul M. ; Klose, Hans ; Matsubara, Hiromi ; Morrell, Nicholas W. ; Peacock, Andrew J. ; Pfeifer, Michael ; Simonneau, Gérald ; Tapson, Victor F. ; Torres, Fernando ; Dario Vizza, Carmine ; Lawrence, David ; Yang, Wei ; Felser, James M. ; Quinn, Deborah A. ; Ghofrani, Hossein-Ardeschir
; Chang, Hyuk-Jae ; Frantz, Robert P. ; Fukumoto, Yoshihiro ; Galié, Nazzareno ; Hassoun, Paul M. ; Klose, Hans ; Matsubara, Hiromi ; Morrell, Nicholas W. ; Peacock, Andrew J. ; Pfeifer, Michael ; Simonneau, Gérald ; Tapson, Victor F. ; Torres, Fernando ; Dario Vizza, Carmine ; Lawrence, David ; Yang, Wei ; Felser, James M. ; Quinn, Deborah A. ; Ghofrani, Hossein-Ardeschir 
Abstract
BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial hypertension (PAH) patients inadequately ...
Owner only: item control page
Altmetric